Skip to main content

Hikma signs licensing agreement with Celltrion for Yuflyma

CT-P17 is the first proposed high concentration, low volume and citrate-free adalimumab biosimilar.

Hikma is set to add strength to its portfolio of biosimilar products.

The company has reached an exclusive licensing agreement with Celltrion and Celltrion Healthcare for Yuflyma (CT-P17), the first adalimumab biosimilar with a high concentration, low volume and citrate-free formulation.

This latest agreement provides Hikma with exclusive rights to commercialize Yuflyma in all of its MENA markets, strengthening its strategic partnership with Celltrion. To date, Hikma has launched three of Celltrion’s biosimilar products, Truxima (rituximab), Remsima (infliximab) and Herzuma (trastuzumab), and is in the process of launching a fourth product, subcutaneous formulation of infliximab, Remsima SC.

[Read more: Hikma enters French generic injectables market]

“Building a portfolio of high value, differentiated products continues to be a key focus area for Hikma,” said Mazen Darwazah, Hikma’s executive vice chairman and president of MENA.

“We are excited to add Yuflyma to our portfolio, strengthening our offering of biosimilar and innovative biologic products. Celltrion’s strong technical capabilities and our well-established commercial presence continues to help us increase patients’ access to important medicines that help them in their treatment journey for these difficult diseases,” Darwazah said. “This agreement builds on our position as the fourth-largest supplier of medicines in MENA and furthers our purpose of putting better health within reach, every day.”

CT-P17 is the first proposed high concentration, low volume and citrate-free adalimumab biosimilar, the company noted.

[Read more: Hikma to acquire Canadian assets of Teligent]

It is indicated for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, uveitis and pediatric uveitis.

This ad will auto-close in 10 seconds